Table 4

Multivariate analyses of elevated EBV antibody titer and low antibody ratio of EBNA-1/EBNA-2 and risk of EBV+ vs EBV Hodgkin lymphoma

AntibodyReferentEBV+ HL cases vs EBV HL cases*EBV+ HL cases vs EBV HL cases
VCA (IgG ≥ 1:2560) < 1:2560 1.3 (0.4-4.2) 0.95 (0.3-3.3) 
EA complex (≥ 1: 40) < 1:40 1.6 (0.5-5.1) 1.2 (0.4-4.2) 
EBNA-1 (≥ 1:1280) < 1:1280 1.1 (0.2-6.5) NA 
EBNA-2 (≥ 1: 80) < 1:80 0.61 (0.2-2.4) NA 
EBNA-1/EBNA-2 ratio (≤ 1.0) > 1.0 NA 14.2 (2.7-74.2) 
AntibodyReferentEBV+ HL cases vs EBV HL cases*EBV+ HL cases vs EBV HL cases
VCA (IgG ≥ 1:2560) < 1:2560 1.3 (0.4-4.2) 0.95 (0.3-3.3) 
EA complex (≥ 1: 40) < 1:40 1.6 (0.5-5.1) 1.2 (0.4-4.2) 
EBNA-1 (≥ 1:1280) < 1:1280 1.1 (0.2-6.5) NA 
EBNA-2 (≥ 1: 80) < 1:80 0.61 (0.2-2.4) NA 
EBNA-1/EBNA-2 ratio (≤ 1.0) > 1.0 NA 14.2 (2.7-74.2) 

Data are RR (95% CI).

NA indicates not applicable.

*

Unconditional logistic regression with mutual control for antibodies to VCA, EA complex, EBNA-1, EBNA-2, and adjusted for age, sex, race, year of serum collection, and histology.

Unconditional logistic regression with mutual control for antibodies to VCA, EA complex, EBNA-1/EBNA-2 ratio ≤ 1.0, and adjusted for age, sex, race, year of serum collection, and histology.

Elevated titer levels.

or Create an Account

Close Modal
Close Modal